



林玟璽 Wen-Ying Lin
主治醫師 Attending Physician

學歷：

2009 - 2019 國立陽明交通大學 醫學系

2013 - 2016 美國密蘇里大學 醫學藥理學博士

經歷：

2026 - 至今 臺北榮總腫瘤醫學部腫瘤內科 主治醫師

2022 - 2026 臺北榮總腫瘤醫學部腫瘤內科 總醫師

2020 - 2023 臺北榮總內科部 住院醫師

2019 - 2020 臺北榮總 不分科住院醫師

2018.03 - 06 美國杜克大學醫學中心 臨床實習

論文發表 (Publications) :

1. **Lin WY**, Tsai CK, Yeh CM, Liu CJ. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. *ToxicolApplPharmacol*2025.
2. Ho YC, Chang MC, **Lin WY**, Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. *J Infect Public Health*2025.
3. Chang MC, Wu PF, Ho YC, **Lin WY**, Wu CY, Liu SY, Liu CJ, Lin YT. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment. *J Infect Public Health*2024.
4. **Lin WY**, Tsai CK, Yeh CM, Chian T, Liu YC, Wang HY, Liu CJ. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. *Cancer Med*2023.
5. Wu WT*, **Lin WY***, Chen YW, Lin CF, Wang HH, Wu SH, Lee YY. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. *Int J Mol Sci*2021. (*Co-first author)
6. **Lin WY**, Wang HH, Chen YW, Lin CF, Fan HC, Lee YY. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. *Int J Mol Sci*2020.
7. **Lin WY**, Chen YW, Lin CF, Yang YP, Wang ML, Hung KF, Chiou SH. Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. *J Chin Med Assoc*2020.
8. Jih KY, **Lin WY**, Sohma Y, Hwang TC. CFTR potentiators: from bench to bedside. *Curr Opin Pharmacol*2017.
9. **Lin WY**, Sohma Y, Hwang TC. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate. *Mol Pharmacol*2016.
10. **Lin WY**, Yu YC. Interaction non grata between CFTR's correctors and potentiators. *Ann Transl Med*2015.
11. **Lin WY**, Jih KY, Hwang TC. A single amino acid substitution in CFTR converts ATP to an inhibitory ligand. *J Gen Physiol*2014.

